Clinical Insights

Every tenth newborn enters the world prematurely, defined as birth before 37 weeks of pregnancy. The World Health Organization recognizes prematurity as a pressing public health concern, bringing various health challenges for these infants and emotional strain to their families. Navigating complex medical needs and enduring emotional burdens during extended hospital stays becomes a reality for these families. Every November 17th, marks #WorldPrematurityDay—a global initiative aimed at raising awareness, advocating for change, promoting research, and supporting premature babies and their families. Unfortunately, the survival rates of preterm babies often hinge on where they are born. On this day, it is crucial to highlight this disparity and ignite change to ensure the best possible healthcare for them, regardless of their birthplace. Recognizing the importance of parenteral nutrition for supporting normal growth and development in premature babies, We need to providing advanced nutrit...

Reported 15-Year Data: The Epic™ Mitral and the Magna Mitral Ease‡ Platforms1,2 Epic Mitral valve delivers excellent durability for patients of different age groups in long-term study.  Clinical Paper - epic-mitral-valve-vs-magna-mitral-ease.pdf Discussion The review examines the longest-published durability data for Biocor™ and Perimount ‡ mitral valves, with initial implants dating back to the early 1980s. Notably, studies by Mykén et al. (2009) and Bourguignon et al. (2014) offer reliable data up to 15 years, capturing over 10% of the original patient cohort for follow-up. Given that Biocor and Perimount are predecessors to the Epic™ Mitral and Magna Mitral Ease‡ valves, respectively, these studies provide crucial insights into the anticipated durability and performance of the latest generation devices. Mykén and team found excellent actuarial freedom from reoperation due to structural valve deterioration (SVD) after 15 years for Biocor valves, with 79.3% overall freedom and 75....